Holding company atop Hanmi Pharmaceutical group, also running early-stage biotech and health-related ventures.
Holding company atop Hanmi Pharmaceutical group, also running early-stage biotech and health-related ventures.
A pure holding company: its income is dividends and brand fees from subsidiaries, so it gets the group's profits only after they are paid out. Hanmi Pharmaceutical is the main operating subsidiary.
Moat: none. Pure holding company; value depends on operating subsidiary Hanmi Pharmaceutical.
Headquarters: Seoul, South Korea · Employees: 489
Size Hanmi Science (008930.KS) is a South Korea Health Care company (Medical Distributors) with a market value of $2.58B, the 113th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩52,400 on 18 Nov 2026.
Performance Over six months the shares gained 48.2%, against +7.6% for the median peer and -37.2% for the South Korea market (cap-weighted) — 3rd highest of 21 in its peer set.
Growth Revenue grew 6.2% over the last twelve months (peer median +5.5%); the operating margin is 4.2% (peer median 3.0%).
Valuation It trades at 2.5× enterprise value to sales against a peer median of 0.5× (most expensive of 21).
Price implies For today's price to make sense, revenue must grow about 26% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is +16 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 1.8 points below its cost of capital (5.6% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩1.43T | ₩1.36T | ₩1.28T | ₩1.25T | ₩1.05T |
| Revenue growth | — | +6% | +3% | +19% | — |
| Gross profit | ₩293B | ₩272B | ₩233B | ₩227B | ₩102B |
| EBITDA | ₩68.6B | ₩66.4B | ₩47.7B | ₩65.7B | ₩33.6B |
| Net income | ₩134B | ₩118B | ₩59.4B | ₩115B | ₩69.2B |
| Free cash flow | ₩21.1B | ₩28.7B | ₩73.2B | ₩28.2B | ₩2.32B |
| Capital expenditure | ₩18.3B | ₩21.0B | ₩11.7B | ₩8.77B | ₩8.44B |
| Total debt | ₩184B | ₩215B | ₩227B | ₩222B | ₩202B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Hanmi Science 008930.KS | $2.58B | +48% | +6% | 4% | 2.5× | 26.0% |
| HanmiPharm 128940.KS | $3.95B | -2% | +14% | 16% | 3.3× | 4.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 008930.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +19.0% | +1.8% | 2nd highest of 21 |
| 6-month return | +48.2% | +7.6% | 3rd highest of 21 |
| Distance from 52-week high | -17.9% | -14.3% | 9th lowest of 21 |
| Revenue growth (TTM) | +6.2% | +5.5% | 10th highest of 21 |
| Operating margin | 4.2% | 3.0% | 8th highest of 21 |
| EV / Sales | 2.5× | 0.5× | most expensive of 21 |
| Growth the price implies (Req g, 7 yrs) | 26.0% | -3.7% | most demanding of 17 |
| Growth delivered (Del g) | +9.6% | +4.6% | 4th highest of 17 |
| Hurdle (Req g minus delivered) | +16.4 pp | -8.9 pp | most demanding of 17 |
| ROIC minus cost of capital | -1.8 pp | +1.7 pp | 3rd lowest of 21 |
| Net debt / EBITDA | 1.2× | 0.5× | 7th most indebted of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Hanmi Science 008930.KS | South Korea | $2.58B | +48% | +6% | 4% | 2.5× | 26.0% | +9.6% |
| Asker Healthcare ASKER.ST | Sweden | $2.69B | -14% | +12% | 7% | 1.8× | 4.7% | +12.7% |
| Alfresa 2784.T | Japan | $2.81B | -3% | +4% | 1% | 0.1× | -8.4% | +3.5% |
| Suzuken 9987.T | Japan | $2.36B | +8% | +5% | 1% | 0.1× | -10.4% | +3.2% |
| COSMOS Pharmaceutical 3349.T | Japan | $3.21B | +2% | +9% | 4% | 0.5× | n/a | n/a |
| Amplifon AMP.MI | Italy | $3.39B | +8% | 0% | 10% | 1.7× | 6.8% | +9.8% |
| MEDIPAL 7459.T | Japan | $3.70B | +15% | +4% | 1% | 0.1× | -7.2% | +3.5% |
| Jointown Pharmaceutical 600998.SS | China | $3.99B | +7% | +9% | 2% | 0.4× | 0.2% | +7.8% |
| Toho 8129.T | Japan | $1.64B | -5% | +4% | 1% | 0.1× | -4.6% | +5.1% |
| Redcare Pharmacy RDC.DE | Germany | $1.50B | +53% | +19% | 0% | 0.5× | n/a | n/a |
| Ship Healthcare 3360.T | Japan | $1.38B | +19% | +6% | 3% | 0.2× | -14.5% | +7.6% |
| Galenica GALE.SW | Switzerland | $5.31B | +8% | +6% | 5% | 1.3× | 7.0% | +3.5% |
| DKSH DKSH.SW | Switzerland | $5.99B | +24% | -1% | 3% | 0.5× | -1.2% | +0.6% |
| Shinva Medical Instrument 600587.SS | China | $1.10B | -10% | +6% | 5% | 0.6× | -6.9% | +1.2% |
| AS ONE 7476.T | Japan | $1.10B | +25% | +10% | 12% | 1.3× | 0.0% | +6.3% |
| DocMorris DOCM.SW | Switzerland | $1.08B | +169% | +11% | -8% | 1.0× | n/a | n/a |
| Shanghai C and D INNOSTIC Medical Technology 301584.SZ | China | $1.06B | -33% | +8% | 3% | 0.5× | -2.7% | +17.9% |
| Nanjing Pharmaceutical 600713.SS | China | $999M | -2% | +3% | 2% | 0.3× | n/a | n/a |
| Sinopharm 1099.HK | Hong Kong | $6.74B | 0% | +3% | 3% | 0.3× | -7.3% | +4.0% |
| Guangxi LiuYao 603368.SS | China | $975M | +1% | +2% | 5% | 0.4× | -9.7% | +6.0% |
| Arjo ARJO-B.ST | Sweden | $974M | +42% | 0% | 8% | 1.3× | -1.0% | +3.9% |